Wilkins Investment Counsel Inc increased Weyerhaeuser (WY) stake by 15.29% reported in 2018Q1 SEC filing. Wilkins Investment Counsel Inc acquired 13,375 shares as Weyerhaeuser (WY)’s stock rose 3.62%. The Wilkins Investment Counsel Inc holds 100,875 shares with $3.53M value, up from 87,500 last quarter. Weyerhaeuser now has $27.97B valuation. The stock decreased 0.83% or $0.31 during the last trading session, reaching $36.95. About 5.42 million shares traded or 31.67% up from the average. Weyerhaeuser Company (NYSE:WY) has risen 11.40% since June 16, 2017 and is uptrending. It has underperformed by 1.17% the S&P500. Some Historical WY News: ; 27/04/2018 – Weyerhaeuser 1Q Net $269M
Camber Capital Management Llc decreased Nektar Therapeutics (NKTR) stake by 55.22% reported in 2018Q1 SEC filing. Camber Capital Management Llc sold 1.85M shares as Nektar Therapeutics (NKTR)’s stock declined 11.70%. The Camber Capital Management Llc holds 1.50 million shares with $159.39 million value, down from 3.35 million last quarter. Nektar Therapeutics now has $9.92 billion valuation. The stock increased 2.57% or $1.45 during the last trading session, reaching $57.86. About 4.74M shares traded or 11.18% up from the average. Nektar Therapeutics (NASDAQ:NKTR) has risen 271.91% since June 16, 2017 and is uptrending. It has outperformed by 259.34% the S&P500. Some Historical NKTR News: ; 16/04/2018 – BRISTOL-MYERS SQUIBB CO – IN STUDY, TWO-YEAR SURVIVAL RATE FOR OPDIVO WAS 16.9% VERSUS 6.0% FOR STANDARD CHEMOTHERAPY; 24/04/2018 – NEW ONCOLOGY CLINICAL PACT BETWEEN NEKTAR & TAKEDA TO EVALUATE; 08/03/2018 – REG-Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer; 08/05/2018 – Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise; 16/04/2018 – PFS RATE AFTER 1 YEAR 43 PCT FOR BRISTOL-MYERS’ OPDIVO PLUS YERVOY VS 13 PCT FOR CHEMOTHERAPY – DATA; 30/04/2018 – Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting; 03/05/2018 – European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy Combination; 26/03/2018 – Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced; 08/05/2018 – X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo® (nivolumab); 13/04/2018 – OPDIVO (NIVOLUMAB), FIRST PD-1 INHIBITOR TO DEMONSTRATE SUPERIOR SURVIVAL BENEFIT COMPARED WITH CHEMOTHERAPY IN A PREDOMINANTLY CHINESE POPULATION WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER…
Investors sentiment decreased to 0.94 in Q1 2018. Its down 0.20, from 1.14 in 2017Q4. It worsened, as 58 investors sold WY shares while 284 reduced holdings. 67 funds opened positions while 256 raised stakes. 556.76 million shares or 2.10% more from 545.30 million shares in 2017Q4 were reported. Boston Common Asset Limited Liability Corporation accumulated 219,861 shares. Financial Bank owns 574,279 shares or 0.27% of their US portfolio. Macquarie Limited, Australia-based fund reported 12,100 shares. Moreover, Barclays Public Limited Liability Com has 0.35% invested in Weyerhaeuser Company (NYSE:WY). Ubs Asset Americas invested 0% in Weyerhaeuser Company (NYSE:WY). Davis R M Inc stated it has 0.23% in Weyerhaeuser Company (NYSE:WY). Finance Advisory Ser invested in 27,687 shares. Capital Ww holds 0.1% or 12.39M shares in its portfolio. Cutler Cap Management holds 152,911 shares or 2.17% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0.15% of its portfolio in Weyerhaeuser Company (NYSE:WY). Edgemoor Advsr Inc holds 113,978 shares or 0.53% of its portfolio. Argyle Capital Inc reported 118,733 shares. Tocqueville Asset Management Limited Partnership holds 0.93% of its portfolio in Weyerhaeuser Company (NYSE:WY) for 2.10M shares. The Ohio-based Victory Capital Mgmt has invested 0% in Weyerhaeuser Company (NYSE:WY). Denver Investment Advsr Ltd Liability Co holds 0.02% of its portfolio in Weyerhaeuser Company (NYSE:WY) for 10,029 shares.
Among 14 analysts covering Weyerhaeuser Company (NYSE:WY), 8 have Buy rating, 1 Sell and 5 Hold. Therefore 57% are positive. Weyerhaeuser Company had 36 analyst reports since September 11, 2015 according to SRatingsIntel. The stock of Weyerhaeuser Company (NYSE:WY) has “Buy” rating given on Thursday, June 22 by BMO Capital Markets. The company was downgraded on Friday, August 12 by Dundee Securities. The firm has “Market Perform” rating by BMO Capital Markets given on Monday, August 14. On Sunday, October 29 the stock rating was maintained by BMO Capital Markets with “Hold”. RBC Capital Markets maintained Weyerhaeuser Company (NYSE:WY) on Monday, September 4 with “Buy” rating. DA Davidson downgraded it to “Neutral” rating and $33 target in Monday, May 9 report. The firm earned “Buy” rating on Thursday, September 22 by Goldman Sachs. The stock of Weyerhaeuser Company (NYSE:WY) earned “Buy” rating by RBC Capital Markets on Friday, October 6. The stock of Weyerhaeuser Company (NYSE:WY) earned “Neutral” rating by Dundee Securities on Friday, December 18. The stock of Weyerhaeuser Company (NYSE:WY) earned “Outperform” rating by Credit Agricole on Friday, November 13.
Wilkins Investment Counsel Inc decreased State Street (NYSE:STT) stake by 8,100 shares to 22,000 valued at $2.19 million in 2018Q1. It also reduced 3M (NYSE:MMM) stake by 2,883 shares and now owns 45,045 shares. Pfizer (NYSE:PFE) was reduced too.
Camber Capital Management Llc increased Wright Med Group N V stake by 240,000 shares to 815,000 valued at $16.17M in 2018Q1. It also upped Medicines Co (NASDAQ:MDCO) stake by 400,000 shares and now owns 2.00 million shares. Atara Biotherapeutics Inc (NASDAQ:ATRA) was raised too.
Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on August, 14. They expect $5.33 earnings per share, up 1,466.67% or $5.72 from last year’s $-0.39 per share. NKTR’s profit will be $913.54 million for 2.71 P/E if the $5.33 EPS becomes a reality. After $-0.60 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -988.33% EPS growth.
Since January 2, 2018, it had 1 buy, and 34 sales for $90.80 million activity. Labrucherie Gil M sold $288,382 worth of stock or 3,477 shares. Shares for $21.85 million were sold by Nicholson John on Tuesday, March 6. ROBIN HOWARD W sold $6.32 million worth of stock or 83,333 shares. KUEBLER CHRISTOPHER A had sold 30,000 shares worth $1.76 million on Tuesday, January 2. $238,453 worth of stock was sold by Hora Maninder on Friday, February 16. Doberstein Stephen K sold $286,445 worth of stock. Thomsen Jillian B. sold $1.41M worth of stock or 13,881 shares.
Among 13 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Nektar Therapeutics had 33 analyst reports since August 6, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, August 30 by Roth Capital. The rating was maintained by Roth Capital with “Buy” on Tuesday, May 30. The rating was maintained by Cowen & Co on Monday, April 9 with “Buy”. The company was maintained on Wednesday, August 9 by Roth Capital. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, January 10. The firm earned “Hold” rating on Wednesday, August 26 by TheStreet. The firm has “Overweight” rating given on Thursday, January 7 by Piper Jaffray. The firm has “Buy” rating given on Friday, April 6 by Mizuho. As per Friday, April 13, the company rating was maintained by PiperJaffray. The stock has “Buy” rating by Aegis Capital on Monday, June 5.